Context Experimental data support the hypothesis that oxidized low-density lipoprotein (LDL) is associated with the metabolic syndrome. However, this hypothesis has not been tested in humans.
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Paul Holvoet, PhD Duk-Hee Lee, MD, PhD Michael Steffes, MD, PhD Myron Gross, PhD David R. Jacobs Jr, PhD P ERSONS WITH THE METABOLIC syndrome are at increased risk of developing type 2 diabetes and coronary heart disease (CHD) as well as increased mortality from CHD and other causes. 1, 2 Findings from the Third National Health and Nutrition Examination Survey showed that prevalence of metabolic syndrome increased with age from 6.7% among participants aged 20 to 29 years, to 43.5% for participants aged 60 to 69 years, and 42.0% for those aged 70 years or older. 3 Several groups developed assays for oxidation-specific epitopes on plasma low-density lipoprotein (LDL). Two assays use antibodies against oxidized phospholipids 4, 5 ; our assay uses the monoclonal antibody (mAb) 4E6 directed against an oxidation-dependent epitope in the apolipoprotein B-100 moiety of LDL. 6, 7 It is generally believed that "fully oxidized LDL" does not exist in the circulation. Blood is rich in antioxidants. In addition, such highly oxidized particles would be rapidly cleared in the liver via scavenger receptors. 8 In contrast, circulating minimally oxidized LDL in which oxidative modification has not been sufficient to cause changes recognized by scavenger receptors was demonstrated. 9 Therefore, all assays for oxidized LDL presumably detect minimally oxidized LDL. This oxidized LDL is only a minor fraction of LDL ranging from 0.001% in healthy controls 10 to approximately 5% in patients with acute coronary events. 6 Because LDL is the substrate for oxida-tion, concentrations of oxidized LDL correlate with LDL concentrations, and in turn with the cholesterol within LDL. In addition, concentrations of oxidized LDL depend on the sensitivity of LDL particles to oxidation; small dense LDL contains smaller amounts of antioxidants and are therefore more prone to oxidation. Previously, metabolic syndrome was shown to be associated with a higher prevalence of small dense LDL. 11 Using the mAb-4E6-based enzymelinked immunosorbent assay (ELISA), we have shown that in the Health, Aging, and Body Composition cohort, a high coronary heart disease risk status (based on the Framingham score) before coronary heart disease events is associated with high concentrations of circulating oxidized LDL, even after adjustment for LDL cholesterol. 12 Be-cause individuals with the metabolic syndrome are at increased risk of macrovascular disease, death, or both, 2, 13 it was no surprise that metabolic syndrome was associated with high concentrations of oxidized LDL. [14] [15] [16] [17] No study, however, has examined the relation between oxidized LDL and the development of the metabolic syndrome. Because biological studies in cellular and animal models do suggest that oxidized LDL contributes to processes that lead to the incidence of metabolic syndrome, 18, 19 we hypothesized that oxidized LDL is associated with the incidence of metabolic syndrome. We tested this hypothesis by determining the association between the concentration of oxidized LDL and the incidence 5 years later of metabolic syndrome and its components.
METHODS
Study Population
The Cardiovascular Risk Development in Young Adults (CARDIA) Study is a longitudinal investigation of CHD risk factors in 5115 men and women between the ages of 18 and 30 years at study inception. Details of the study design, recruitment, and procedures have been published elsewhere. 20, 21 Participants were recruited between 1985 and 1986 at 4 US clinical sites: Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California. Participants were reexamined at 2, 5, 7, 10, 15, and 20 years after inception, with reexamination rates among surviving cohort members of 90% at 2, 86% at 5, 81% at 7, 79% at 10, 74% at 15, and 72% at 20 years. All participants signed extensive consent forms at each examination, with all aspects reviewed and approved by the institutional review board of each participating institution. The full CARDIA Study sample at baseline was balanced by age (45% aged 18-24 years; 55% aged 25-30 years), race (52% African American; 48% white), sex (46% men; 54%, women), and educational achievement (40% completed 12 years; 60% Ͼ12 years).
Oxidized LDL was assessed in 2823 participants at year 15 (2000-2001) as part of the Young Adult Longitudinal Trends in Antioxidants (YALTA) ancillary study to CARDIA. Among them, we excluded participants who were pregnant, did not fast at least 8 hours, or had missing data (FIGURE). Metabolic syndrome components were defined as detailed in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) report 22 : (1) waist circumference of 102 cm or more in men and 88 cm or more in women;
(2) fasting triglycerides of 150 mg/dL or more; (3) HDL cholesterol of less than 40 mg/dL in men and less than 50 mg/dL in women; (4) blood pressure of 130/85 mm Hg or higher or taking antihypertensive medication; and (5) fasting glucose 100 mg/dL or higher or taking antidiabetic medication. Persons with at least 3 of these characteristics were defined as having metabolic syndrome. 23, 24 At year 15, 372 participants (14.2%) were diagnosed with metabolic syndrome (Figure) and were excluded from this longitudinal study. We also excluded participants who were pregnant, did not fast at least 8 hours, and had missing data. Incident metabolic syndrome was diagnosed at year 20 (2005-2006) in 12.9% (243 of 1889) of participants. Among them, 71 were taking antihypertensive medication; 13, antidiabetic medication; and 13, cholesterol-lowering medication.
To convert triglycerides to millimoles per liter, multiply by 0.0113; HDL, LDL, and total cholesterol to millimoles per liter, multiply by 0.0259; and glucose to millimoles per liter, multiply by 0.0555.
Measurements
Information on demographic characteristics (age, sex, and race) and educational achievement was self-reported on standardized questionnaires during each examination. The participant selfreported race of both natural mother and natural father as "white, not Hispanic" or "black, not Hispanic," and was assigned parental race (mixed race excluded). During the examination, 15 and 20 (2005-2006 ). a Participants could be excluded for more than 1 reason.
height and weight were measured. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. 2 Waist circumference was measured as the abdominal girth midway between the iliac crest and the bottom of the ribcage. Hip circumference was determined at the maximum protrusion of the hips at the level of the symphysis pubis.
Smoking was measured as selfreported current smoking status (nonsmoker, ex-smoker, and current smoker). Habitual physical activity was measured by use of the CARDIA Physical Activity History, a simplified version of the Minnesota Leisure Time Physical Activity Questionnaire. 24 Three seated blood pressure measurements were obtained with a random-zero sphygmomanometer; the mean of the second and third readings was used for this report.
Participants were asked to avoid smoking and heavy physical activity for at least 2 hours before each examination and those included herein were fasting at least 8 hours. Blood was taken from participants, and centrifuged, with aliquots stored at −70°C until shipped on dry ice to a central laboratory. All laboratory assessments were performed without knowledge of other CARDIA data. Plasma lipids were measured in samples of participants at year 15 and 20 at the University of Washington Northwest Lipid Research Clinic Laboratory (Seattle). Total cholesterol and triglycerides were measured by enzymatic methods. High-density lipoprotein (HDL) cholesterol was assayed after dextran sulfatemagnesium precipitation, and LDL cholesterol was estimated from the Friedewald equation. 25 The 25 individuals with triglycerides higher than 400 mg/ dL were excluded from this calculation. Concentrations of oxidized LDL were measured in year 15 plasma samples at the Atherosclerosis and Metabolism Unit in Leuven by means of an mAb-4E6based competition ELISA (Mercodia, Uppsala, Sweden). mAb-4E6 is directed against a conformational epitope in the apolipoprotein B-100 moiety of LDL that is generated as a consequence of the substitution of 60 lysine residues of apolipoprotein B-100 with aldehydes. Substituting aldehydes can be produced by peroxidation of lipids of LDL, which results in the generation of oxidized LDL. However, lipid peroxidation is not required. Indeed, aldehydes that are released by endothelial cells under oxidative stress or by activated platelets may also induce the oxidative modification of apolipoprotein B-100 in the absence of peroxidation of lipids of LDL. 26 The analytical performance of this assay has beendescribedelsewhere. 27 Itscoefficient of variation was 7.4%. Serum glucose was measured by means of hexokinase coupled to glucose-6-phosphate dehydrogenase, as was serum insulin with an immunoassay (Linco Research Inc, St Louis,Missouri).High-sensitivityELISAs measured serum C-reactive protein at the Department of Pathology, University of Vermont, as described previously. 28 Adiponectin was measured in serum by radioimmunoassay at Linco Research, using a polyclonal antibody raised in a rabbit and purified recombinant adiponectin standards with an effective range of 0.2 to 40 mg/L. 29 
Statistical Analyses
Longitudinal associations were studied between year 15 plasma oxidized LDL as the independent variable of interest and year 20 metabolic syndrome as the dependent variable among individuals free of prevalent metabolic syndrome at year 15. Multiple logistic regression was used to examine the association of the quintiles of oxidized LDL and metabolic syndrome and its constituent risk factors, adjusted for age (years), sex, race, and study center. Further year 15 covariates in the fully adjusted model included cigarette smoking, BMI, physical activity, and LDL cholesterol. C-reactive protein, adiponectin, and antidiabetic, antihypertensive, and cholesterol-lowering medication were separately considered as possible mediators in the associations. We also established associations between LDLcholesterolandmetabolicsyndrome to compare with those of oxidized LDL, after adjusting for each other. All analyses were performed with SAS version 9.1 (SASInstituteInc,Cary,NorthCarolina).
A P value of less than .05 was considered statistically significant.
RESULTS
Among the 1889 participants included in the longitudinal analyses, oxidized LDL was positively associated with male sex, black race, BMI, and obesity (BMI Ͼ30), all metabolic syndrome components, and C-reactive protein (TABLE 1) . Oxidized LDL had a correlation coefficient with LDL cholesterol of 0.6 and was inversely associated with HDL cholesterol and adiponectin. In contrast, LDL cholesterol was not related to race and C-reactive protein.
Oxidized LDL showed a graded relation to incident metabolic syndrome, amounting to an adjusted odds ratio (OR) of 3.5 in the top quintile of oxidized LDL compared with the lowest quintile in the fully adjusted model that includedage,sex,race,studycenter,cigarette smoking, BMI, physical activity, and LDL cholesterol ( Low-density lipoprotein cholesterol was associated with the metabolic syndrome when adjusting for age, sex, race, and study center. This association was not significant when adjusting further for year 15 cigarette smoking, physical activity, and BMI. There was no association after adjustment for oxidized LDL ( Table 2) .
The ORs for incidence of dichotomous components of metabolic syndrome in the top quintile compared with the lowest quintile of oxidized LDL (adjusted as in model 3 of Table 2 including LDL cholesterol) were 2.4 (95% CI, 1.5-3.8; P for trend=.002) for high fast-ing glucose (Ն100 mg/dL or taking antidiabetic medication), 2.1 (95% CI, 1.2-3.6; P for trend=.004) for abdominal obesity, and 2.1 (95% CI, 1.1-4.0; P for trend=.008) for triglycerides but was not significant for blood pressure or HDL cholesterol (TABLE 3) . Numbers of study participants at risk at year 15 for incidence of each metabolic syndrome component at year 20 were 1635 for high blood pressure, 1851 for high fasting glucose, 1525 for abdominal obesity, 1344 for low HDL cholesterol, and 1741 for high triglycerides. Low-density lipoprotein cholesterol was not associated with Abbreviations: BMI, body mass index, which is calculated as weight in kilograms divided by height in meters squared; HDL, high-density lipoprotein; LDL, low-density lipoprotein. SI conversion factors: To convert glucose to millimoles per liter, multiply values by 0.0555; C-reactive protein to nanomoles per liter, multiply by 9.524; HDL cholesterol to millimoles per liter, multiply by 0.0259; and triglycerides to millimoles per liter, multiply by 0.0113. a Tabulated data are linear regression estimates of means that were adjusted for age, sex, race, and study center.
incidence of any of the metabolic syndrome components (Table 3) .
COMMENT
This population-based study showed that oxidized LDL, a marker of oxidative stress specific to LDL particles, was significantly associated with the incidence of metabolic syndrome. In particular, oxidized LDL was associated with 2 of the 3 metabolic syndrome factors defined according to ATPIII: (1) the central metabolic factor comprising obesity and hypertriglycemia and (2) the glucose factor, as previously defined. 30, 31 Oxidized LDL was not associated with elevated blood pressure or HDL cholesterol. These associations remained significant after adjustment for age, sex, race, smoking, physical activity, and LDL cholesterol. These associations also remained significant after adjustment for C-reactive protein, adiponectin, and antihypertensive, and antidiabetic and cholesterollowering medication. In contrast, LDL cholesterol showed only a limited relation with metabolic syndrome, which tended to become flat in the fully adjusted model including oxidized LDL.
A novel finding of this study is that oxidized LDL was associated with incident metabolic syndrome. As yet, it is not possible to conclude whether oxidized LDL is a marker related to mechanistic underlying factors on the pathway to the development of metabolic syndrome, or whether it is by itself a functional intermediary in this pathway. However, the strong association of oxidized LDL with the incidence of metabolic syndrome is consistent with a causal role.
Our data are in agreement with the previous observation that circulating oxidized LDL is associated with obesity and that weight loss results in a decrease of oxidized LDL. 32 This association may be explained by the occurrence of small dense LDL that is more prone to oxidation. 11 Another possible explanation is that adipose tissue contributes to the oxidation of LDL by 2 biochemical actions. First, greater adipose tissue may increase production of arachidonate-5-lipoxygenase, which catalyzes LDL oxidation. Second, greater adipose tissue may decrease production of superoxide dismutase, which prevents LDL oxidation. 33 Our longitudinal data suggest that oxidized LDL may be associated with the increase of adipose tissue in agreement with experimental findings that oxidized LDL contributes either directly by contributing to the hyperplasia and the hypertrophy of adipocytes 18 or indirectly by increasing the infiltration of activated monocytes/ macrophages, which increase adipogenesis. 34 Interestingly, we observed a higher prevalence of obesity in the higher quintiles of oxidized LDL.
In addition, the observed association between glycemia and oxidized LDL is in agreement with the observation that even in healthy, nondiabetic persons, plasma glucose correlated with a higher susceptibility of in vitro oxidation of LDL, 35 and glycemia was associated with increased in vivo LDL oxidation, reflected by higher prevalence of highly oxidized LDL. 14 The association between oxidized LDL and glycemia could be due to reducing insulinsignaling 36 and reducing glucose uptake by oxidized LDL. 19 Finally, our data support the association between oxidized LDL and dyslipidemia in humans, 15, 37 which could be due to impairing of triglyceride storage and secretion by oxidized LDL. 38 
Study Strengths and Limitations
The strengths of the present study include the large community-based sample, the availability of many standardized clinical covariates, and the generalizability of our findings to men and women and whites and African Americans, even though the age range from 33 to 45 years at year 15 was narrow. The study had 85% power in a 2-sided z test for proportions with type 1 error of 5% to detect an OR of 1.95 for metabolic syndrome comparing the highest with the lowest quintile of oxidized LDL. Although our population-based data agree with molecular mechanistic data in cellular and animal models suggesting that oxidized LDL is biologically relevant for the development of metabolic syndrome, our data do not prove a causal role of metabolic syndrome or its constituent risk factors; indeed, oxidized LDL was cross-sectionally correlated with components of the metabolic syn-drome within the 1889 people studied herein. Another limitation is the exclusion of a number, though limited, of participants because of pregnancy and missing samples or data. Previously, it was questioned whether a single reading adequately represents the oxidized LDL profiles of participants. However, we have recently shown that the betweenperson variability of oxidized LDL measured by ELISA assay was 74% (with the remaining 26% being within-person and analytical variance), and that this value was comparable with that of highsensitivity C-reactive protein and cho-lesterol measured by means of automated tests. 27 A limitation is however that only freshly frozen samples can be analyzed; several thawing and freezing cycles can lead to further in vitro oxidation.
CONCLUSION
Our population-based data show that higher concentrations of circulating oxidized LDL are associated with the incidence of metabolic syndrome and the accumulation of 3 of its risk factor constituents: obesity, hyperglycemia, and hypertriglyceridemia. Abbreviations: CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio. SI conversion factors: To convert LDL cholesterol to millimoles per liter, multiply values by 0.0259. a Data are adjusted for age, sex, race, study center, cigarette smoking, physical activity, body mass index (calculated as weight in kilograms divided by height in meters squared), and LDL cholesterol or oxidized LDL (body mass index was not included in the model when abdominal obesity was the dependent variable). Each row is a separate logistic regression model in which prevalent cases of the dependent variable (that is, each component of metabolic syndrome) were excluded. The 5 metabolic syndrome components are defined in the "Methods" section.
